课题基金 / 基金详情

Using microbubbles to increase the destruction of liver tumors by high-intensity focused ultrasound

Using microbubbles to increase the destruction of liver tumors by high-intensity focused ultrasound
利用微泡通过高强度聚焦超声增加对肝脏肿瘤的破坏
批准号:
15390228
负责人:
MARUYAMA Toshiyuki
金额:
$8.13万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

MARUYAMA Toshiyuki的其他基金

相似基金

相关文献

中文摘要
翻译
为探讨高强度聚焦超声(HIFU)与微气泡剂联合治疗肝细胞癌的可行性。HIFU换能器直径40 mm,产生2.18 MHz连续波30s。空间峰值时间平均强度为600W/cm2。经二甲基亚硝胺(100ppm)诱导大鼠肝肿瘤形成。麻醉大鼠,剖腹手术后,静脉注射微泡剂Levovist或生理盐水。在HIFU照射后即刻,评估HIFU区域的超声图像。HIFU后肝组织平均高回声区体积为(mm~3,Levovist:355.3±180.7 vs.47.4±35.6,p<0.001,n=13),HIFU凝固肝组织体积为(mm~3,Levovist:275.3±120.0 vs.60.1±23.6p<0.001,n=13)。显微镜下可见高强度聚焦超声照射区域内爆裂性包囊,许多癌细胞被破坏或完全破坏。一些肿瘤细胞因细胞膜或细胞核丢失而变形。结论:微气泡剂利沃司特通过增加高强度聚焦超声的作用,在抗癌治疗中也有直接作用。
英文摘要
We studied the possibility of using high-intensity focused ultrasound (HIFU) together with a microbubble agent to treat hepatocellular carcinoma.The transducer for HIFU was 40 mm in diameter ; it produced a continuous 2.18-MHz wave for 30 seconds.The spatial peak temporal average intensity was 600 W/cm2.Development of liver tumors in rats was induced by administration of Dimethylnitrosamin (100 ppm).Rats with liver tumors were anesthetized, underwent laparotomy, and were given the microbubble agent Levovist or saline intravenously.After 60 seconds of Levovist or saline injection, the liver was exposed to HIFU for 30 seconds. Immediately after HIFU exposure, ultrasound images of the HIFU area were evaluated. Then the liver was excised and the volume of coagulated tissue was measured.The mean volume of hyperechoic areas after HIFU were as follows (mm3, Levovist vs. saline : 355.3 ± 180.7 vs. 47.4 ± 35.6, p < 0.001, n=13).The volumes of liver tissue coagulated by HIFU were as follows (mm3, Levovist vs. saline : 275.3 ± 120.0 vs. 60.1 ± 23.6, p < 0.001, n=13).On microscopic examination of areas exposed to HIFU, implosion cysts were seen, and many cancer cells were found to have been disrupted or destroyed completely.Some tumor cells had been distorted by loss of cell membranes or nuclei.In conclusion, the microbubble agent Levovist, by increasing the effect of HIFU, could also have a direct role in anti-cancer therapy.
期刊论文(64)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s00330-005-2663-7
发表时间: 2005-07-01
期刊: EUROPEAN RADIOLOGY
影响因子: 5.9
作者: [Kaneko, Y, Maruyama, T, Matsumoto, Y]
通讯作者: Matsumoto, Y
DOI: 10.1016/j.ultrasmedbio.2004.07.016
发表时间: 2004-10-01
期刊: ULTRASOUND IN MEDICINE AND BIOLOGY
影响因子: 2.9
作者: [Takegami, K, Kaneko, Y, Nagawa, H]
通讯作者: Nagawa, H
18F-FDG PET for hepatocellular carcinoma presenting with portal vein thrombus.
18F-FDG PET 用于诊断伴有门静脉血栓的肝细胞癌。
DOI: --
发表时间: 2005
期刊: Journal of Gastroenterology. 40
影响因子: --
作者: [Hanajiri K, Mitsui H, Maruyama T, Kondo Y, Shiina S, Omata M, Nakagawa K.]
通讯作者: Nakagawa K.
DOI: 10.1002/hep.1840380408
发表时间: 2003-10
期刊: Hepatology
影响因子: 13.5
作者: [T. Tsutsumi;Tetsuro Suzuki;K. Moriya;Y. Shintani;H. Fujie;H. Miyoshi;Y. Matsuura;K. Koike;T. Miyamura]
通讯作者: T. Tsutsumi;Tetsuro Suzuki;K. Moriya;Y. Shintani;H. Fujie;H. Miyoshi;Y. Matsuura;K. Koike;T. Miyamura
共 21 条
    The comparison of virus genome and immune reaction between asymptomatic carriers and chronic hepatitis patients infected with HBV.
    • 批准号:
      13670495
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $0.64万
    • 财政年份:
      2001
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    The mechanism which causes fulminant hepatic failure after immune suppression therapy on HBV carrier patients
    • 批准号:
      11670480
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.92万
    • 财政年份:
      1999
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    Investigation for the development of vaccine against hepatitis C virus
    • 批准号:
      09670515
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.98万
    • 财政年份:
      1997
    • 负责人:
      MARUYAMA Toshiyuki
    • 依托单位:
    国内基金
    海外基金
    Microbubble-ZPDGFRβ/PFD/liposome通过靶向肝星状细胞改善肿瘤微环境抑制肝细胞癌复发转移的作用及机制研究
    • 批准号:
      82272000
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      杨秀华
    • 依托单位:
    超声微泡造影剂携靶基因治疗及其声像图监控研究
    • 批准号:
      30430230
    • 项目类别:
      重点项目
    • 资助金额:
      130.0万元
    • 批准年份:
      2004
    • 负责人:
      王志刚
    • 依托单位:
    超声微泡介导基因转染过程适宜空化效果的研究
    • 批准号:
      30400419
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2004
    • 负责人:
      修建成
    • 依托单位:
    超声微泡造影剂介导靶基因治疗梗死性血管病及机制研究
    • 批准号:
      30370402
    • 项目类别:
      面上项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2003
    • 负责人:
      王志刚
    • 依托单位: